Gemphire Therapeutics Inc. (NASDAQ:GEMP)‘s stock had its “buy” rating reissued by equities researchers at Canaccord Genuity in a research report issued on Thursday. They currently have a $17.00 price objective on the stock. Canaccord Genuity’s price target points to a potential upside of 84.18% from the stock’s current price.
Other research analysts also recently issued reports about the stock. Zacks Investment Research downgraded shares of Gemphire Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, November 7th. Jefferies Group reiterated a “buy” rating and set a $17.00 price objective (up from $15.00) on shares of Gemphire Therapeutics in a research note on Tuesday, October 18th. Finally, RBC Capital Markets reiterated an “outperform” rating and set a $25.00 price objective on shares of Gemphire Therapeutics in a research note on Friday, September 16th. One investment analyst has rated the stock with a sell rating and five have assigned a buy rating to the company’s stock. Gemphire Therapeutics currently has an average rating of “Buy” and a consensus target price of $20.80.